Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men

Julia Price; Jennifer Frances Hoy; Emma Jean Ridley; Ibolya Barbara Nyulasi; Eldho Paul; Ian John Woolley

doi:10.1071/SH14084

Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men

Julia Price, Jennifer Frances Hoy, Emma Jean Ridley, Ibolya Barbara Nyulasi, Eldho Paul, Ian John Woolley

Research output: Contribution to journal › Article › Research › peer-review

32 Citations (Scopus)

Abstract

Background: Although it significantly improves HIV-related outcomes, some components of combination antiretroviral therapy (ART) cause lipodystrophy syndrome. The composition of combination ART has changed over time but the impact on lipodystrophy prevalence is unknown. Methods: One hundred HIV-infected males underwent dual-energy X-ray absorptiometry scanning, serum lipid testing and completed a questionnaire in a cross-sectional study in 2010. Thirty-four participants of a 1998 study cohort were re-evaluated in 2010. The same parameters were used to define and compare lipodystrophy, metabolic syndrome and cardiovascular disease (CVD) risk in the two time periods. Results: In 2010, the prevalence of lipodystrophy was lower when compared with 1998 (53 v. 69 , P=0.012), despite higher mean age (51.8 v. 42.1 years, P

Original language	English
Pages (from-to)	240 - 248
Number of pages	9
Journal	Sexual Health
Volume	12
Issue number	3
DOIs	https://doi.org/10.1071/SH14084
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1071/SH14084

3597484-oaFinal published version, 164 KB

http://www.publish.csiro.au/?act=view_file&file_id=SH14084.pdf

Cite this

@article{b050f5e4226f4f7fac2484e34c5078ac,

title = "Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men",

abstract = "Background: Although it significantly improves HIV-related outcomes, some components of combination antiretroviral therapy (ART) cause lipodystrophy syndrome. The composition of combination ART has changed over time but the impact on lipodystrophy prevalence is unknown. Methods: One hundred HIV-infected males underwent dual-energy X-ray absorptiometry scanning, serum lipid testing and completed a questionnaire in a cross-sectional study in 2010. Thirty-four participants of a 1998 study cohort were re-evaluated in 2010. The same parameters were used to define and compare lipodystrophy, metabolic syndrome and cardiovascular disease (CVD) risk in the two time periods. Results: In 2010, the prevalence of lipodystrophy was lower when compared with 1998 (53 v. 69 , P=0.012), despite higher mean age (51.8 v. 42.1 years, P",

author = "Julia Price and Hoy, {Jennifer Frances} and Ridley, {Emma Jean} and Nyulasi, {Ibolya Barbara} and Eldho Paul and Woolley, {Ian John}",

year = "2015",

doi = "10.1071/SH14084",

language = "English",

volume = "12",

pages = "240 -- 248",

journal = "Sexual Health",

issn = "1448-5028",

publisher = "CSIRO Publishing",

number = "3",

}

TY - JOUR

T1 - Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men

AU - Price, Julia

AU - Hoy, Jennifer Frances

AU - Ridley, Emma Jean

AU - Nyulasi, Ibolya Barbara

AU - Paul, Eldho

AU - Woolley, Ian John

PY - 2015

Y1 - 2015

N2 - Background: Although it significantly improves HIV-related outcomes, some components of combination antiretroviral therapy (ART) cause lipodystrophy syndrome. The composition of combination ART has changed over time but the impact on lipodystrophy prevalence is unknown. Methods: One hundred HIV-infected males underwent dual-energy X-ray absorptiometry scanning, serum lipid testing and completed a questionnaire in a cross-sectional study in 2010. Thirty-four participants of a 1998 study cohort were re-evaluated in 2010. The same parameters were used to define and compare lipodystrophy, metabolic syndrome and cardiovascular disease (CVD) risk in the two time periods. Results: In 2010, the prevalence of lipodystrophy was lower when compared with 1998 (53 v. 69 , P=0.012), despite higher mean age (51.8 v. 42.1 years, P

AB - Background: Although it significantly improves HIV-related outcomes, some components of combination antiretroviral therapy (ART) cause lipodystrophy syndrome. The composition of combination ART has changed over time but the impact on lipodystrophy prevalence is unknown. Methods: One hundred HIV-infected males underwent dual-energy X-ray absorptiometry scanning, serum lipid testing and completed a questionnaire in a cross-sectional study in 2010. Thirty-four participants of a 1998 study cohort were re-evaluated in 2010. The same parameters were used to define and compare lipodystrophy, metabolic syndrome and cardiovascular disease (CVD) risk in the two time periods. Results: In 2010, the prevalence of lipodystrophy was lower when compared with 1998 (53 v. 69 , P=0.012), despite higher mean age (51.8 v. 42.1 years, P

U2 - 10.1071/SH14084

DO - 10.1071/SH14084

M3 - Article

SN - 1448-5028

VL - 12

SP - 240

EP - 248

JO - Sexual Health

JF - Sexual Health

IS - 3

ER -